An outcomes-based arrangement between Highmark and Boehringer Ingelheim has resulted in a overall charge of treatment reduction above more than twenty% for adult patients with
An outcomes-based arrangement between Highmark and Boehringer Ingelheim has resulted in a overall charge of treatment reduction above more than twenty% for adult patients with